BofA cuts AbbVie (ABBV) target while maintaining neutral view
I'm PortAI, I can summarize articles.
BofA has reduced its price target for AbbVie Inc. (NYSE:ABBV) from $248 to $233 while maintaining a Neutral rating. Despite this adjustment, AbbVie is still recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2026, with BofA noting a favorable growth outlook for the company.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments